Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis

Felicita Andreotti; Bianca Rocca; Steen Husted; Ramzi A. Ajjan; Jurrien Ten Berg; Marco Cattaneo; Jean-Philippe Collet; Raffaele De Caterina; Keith A. A. Fox; Sigrun Halvorsen; Kurt Huber; Elaine M. Hylek; Gregory Y. H. Lip; Gilles Montalescot; Joao Morais; Carlo Patrono; Freek W. A. Verheugt; Lars Wallentin; Thomas W. Weiss; Robert F. Storey

doi:10.1093/eurheartj/ehv304

Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis

Felicita Andreotti, Bianca Rocca, Steen Husted, Ramzi A. Ajjan, Jurrien Ten Berg, Marco Cattaneo, Jean-Philippe Collet, Raffaele De Caterina, Keith A. A. Fox, Sigrun Halvorsen, Kurt Huber, Elaine M. Hylek, Gregory Y. H. Lip, Gilles Montalescot, Joao Morais, Carlo Patrono, Freek W. A. Verheugt, Lars Wallentin, Thomas W. Weiss, Robert F. Storey

Risultato della ricerca: Contributo in rivista › Articolo in rivista › peer review

139 Citazioni (Scopus)

Abstract

Contemporary medicine is shifting towards person rather than disease-oriented care.1With increasing life expectancy and the ageing of baby boomers, the proportion over 60 years is growing faster than the overall population, with worldwide estimates reaching 2 billion by 2050 (http://www.un.org/esa/population/publications/ worldageing19502050).2 In parallel, acute coronary syndromes (ACS) and atrial fibrillation (AF)—the most frequent indications for dual platelet inhibition or anticoagulation—occur mostly in older patients.2 – 6 There is general agreement that people ≥75 years can be defined ‘elderly’; however, cutoffs as low as 65 years have been applied to important clinical datasets and risk scores.3,7 – 10

Lingua originale	English
pagine (da-a)	3238-3249
Numero di pagine	12
Rivista	European Heart Journal
Volume	36
DOI	https://doi.org/10.1093/eurheartj/ehv304
Stato di pubblicazione	Pubblicato - 2015

Keywords

antithrombotic therapy
elderly

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Accesso al documento

10.1093/eurheartj/ehv304

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

Andreotti, F., Rocca, B., Husted, S., Ajjan, R. A., Berg, J. T., Cattaneo, M., Collet, J.-P., Caterina, R. D., Fox, K. A. A., Halvorsen, S., Huber, K., Hylek, E. M., Lip, G. Y. H., Montalescot, G., Morais, J., Patrono, C., Verheugt, F. W. A., Wallentin, L., Weiss, T. W., & Storey, R. F. (2015). Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis. European Heart Journal, 36, 3238-3249. https://doi.org/10.1093/eurheartj/ehv304

@article{a0e5a36db3ee4814ae7de00788cfdb4d,

title = "Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis",

abstract = "Contemporary medicine is shifting towards person rather than disease-oriented care.1With increasing life expectancy and the ageing of baby boomers, the proportion over 60 years is growing faster than the overall population, with worldwide estimates reaching 2 billion by 2050 (http://www.un.org/esa/population/publications/ worldageing19502050).2 In parallel, acute coronary syndromes (ACS) and atrial fibrillation (AF)—the most frequent indications for dual platelet inhibition or anticoagulation—occur mostly in older patients.2 – 6 There is general agreement that people ≥75 years can be defined {\textquoteleft}elderly{\textquoteright}; however, cutoffs as low as 65 years have been applied to important clinical datasets and risk scores.3,7 – 10",

keywords = "antithrombotic therapy, elderly, antithrombotic therapy, elderly",

author = "Felicita Andreotti and Bianca Rocca and Steen Husted and Ajjan, {Ramzi A.} and Berg, {Jurrien Ten} and Marco Cattaneo and Jean-Philippe Collet and Caterina, {Raffaele De} and Fox, {Keith A. A.} and Sigrun Halvorsen and Kurt Huber and Hylek, {Elaine M.} and Lip, {Gregory Y. H.} and Gilles Montalescot and Joao Morais and Carlo Patrono and Verheugt, {Freek W. A.} and Lars Wallentin and Weiss, {Thomas W.} and Storey, {Robert F.}",

year = "2015",

doi = "10.1093/eurheartj/ehv304",

language = "English",

volume = "36",

pages = "3238--3249",

journal = "European Heart Journal",

issn = "0195-668X",

publisher = "Oxford University Press",

}

Andreotti, F, Rocca, B, Husted, S, Ajjan, RA, Berg, JT, Cattaneo, M, Collet, J-P, Caterina, RD, Fox, KAA, Halvorsen, S, Huber, K, Hylek, EM, Lip, GYH, Montalescot, G, Morais, J, Patrono, C, Verheugt, FWA, Wallentin, L, Weiss, TW & Storey, RF 2015, 'Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis', European Heart Journal, vol. 36, pagg. 3238-3249. https://doi.org/10.1093/eurheartj/ehv304

TY - JOUR

T1 - Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis

AU - Andreotti, Felicita

AU - Rocca, Bianca

AU - Husted, Steen

AU - Ajjan, Ramzi A.

AU - Berg, Jurrien Ten

AU - Cattaneo, Marco

AU - Collet, Jean-Philippe

AU - Caterina, Raffaele De

AU - Fox, Keith A. A.

AU - Halvorsen, Sigrun

AU - Huber, Kurt

AU - Hylek, Elaine M.

AU - Lip, Gregory Y. H.

AU - Montalescot, Gilles

AU - Morais, Joao

AU - Patrono, Carlo

AU - Verheugt, Freek W. A.

AU - Wallentin, Lars

AU - Weiss, Thomas W.

AU - Storey, Robert F.

PY - 2015

Y1 - 2015

N2 - Contemporary medicine is shifting towards person rather than disease-oriented care.1With increasing life expectancy and the ageing of baby boomers, the proportion over 60 years is growing faster than the overall population, with worldwide estimates reaching 2 billion by 2050 (http://www.un.org/esa/population/publications/ worldageing19502050).2 In parallel, acute coronary syndromes (ACS) and atrial fibrillation (AF)—the most frequent indications for dual platelet inhibition or anticoagulation—occur mostly in older patients.2 – 6 There is general agreement that people ≥75 years can be defined ‘elderly’; however, cutoffs as low as 65 years have been applied to important clinical datasets and risk scores.3,7 – 10

AB - Contemporary medicine is shifting towards person rather than disease-oriented care.1With increasing life expectancy and the ageing of baby boomers, the proportion over 60 years is growing faster than the overall population, with worldwide estimates reaching 2 billion by 2050 (http://www.un.org/esa/population/publications/ worldageing19502050).2 In parallel, acute coronary syndromes (ACS) and atrial fibrillation (AF)—the most frequent indications for dual platelet inhibition or anticoagulation—occur mostly in older patients.2 – 6 There is general agreement that people ≥75 years can be defined ‘elderly’; however, cutoffs as low as 65 years have been applied to important clinical datasets and risk scores.3,7 – 10

KW - antithrombotic therapy

KW - elderly

KW - antithrombotic therapy

KW - elderly

UR - http://hdl.handle.net/10807/68473

U2 - 10.1093/eurheartj/ehv304

DO - 10.1093/eurheartj/ehv304

M3 - Article

SN - 0195-668X

VL - 36

SP - 3238

EP - 3249

JO - European Heart Journal

JF - European Heart Journal

ER -

Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis

Abstract

Keywords

OSS delle Nazioni Unite

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo